benzyl 2,3,4-tri-O-benzyl-β-D-glucopyranoside 6-(hydrogen succinate) | 566905-73-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 糖脂
• 英文名称: benzyl 2,3,4-tri-O-benzyl-β-D-glucopyranoside 6-(hydrogen succinate)
• 英文别名: 4-oxo-4-[[(2R,3R,4S,5R,6R)-3,4,5,6-tetrakis(phenylmethoxy)oxan-2-yl]methoxy]butanoic acid
• CAS: 566905-73-5
• 化学式: C₃₈H₄₀O₉
• 分子量: 640.73
• InChiKey: WREKUGLWDNYAAP-OXRFRVAUSA-N

物化性质

• 沸点：
  765.3±60.0 °C(Predicted)
• 密度：
  1.26±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  47
• 可旋转键数：
  18
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  110
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  8-(5-cholesten-3α-yloxy)-3n³₆-dioxaoctan-1-ol 、 benzyl 2,3,4-tri-O-benzyl-β-D-glucopyranoside 6-(hydrogen succinate) 在 4-二甲氨基吡啶 、 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 以70%的产率得到
  参考文献：
  名称：

  Design, synthesis and biological evaluation of multivalent glucosides with high affinity as ligands for brain targeting liposomes

  摘要：

  The new bifunctional cluster glucosides were designed and synthesized as liposome ligands for preparing novel liposome to achieve the effective delivery of drug formulations to brain by GLUT1. Docetaxel-loaded five liposomes were prepared successfully and tested in the animals. Results from the in vivo distribution study after i.v. administration of these five liposomes and blank-docetaxel indicated that the coupled liposomes Lip-1, Lip-2, Lip-3, Lip-5 exhibited excellent transport ability across the BBB. In particular, they significantly increased the level of docetaxel in brain compared to blank-docetaxel and Lip. Among them, Lip-5 showed higher brain concentration. Both pharmacokinetics and distribution study in mice confirmed that this novel brain targeting drug delivery system was a promising carrier to enhance brain delivery capacity for CNS drugs. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.10.007
• 作为产物：
  描述：

  苄基 alpha-D-吡喃葡萄糖苷 在 4-二甲氨基吡啶 、 sodium hydride 、 对甲苯磺酸 作用下， 以 吡啶 、 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 29.17h， 生成 benzyl 2,3,4-tri-O-benzyl-β-D-glucopyranoside 6-(hydrogen succinate)
  参考文献：
  名称：

  Synthesis of glycosyl derivatives as dopamine prodrugs: interaction with glucose carrier GLUT-1Electronic supplementary information (ESI) available: experimental details for the preparation of all derivatives and biological assays. See http://www.rsc.org/suppdata/ob/b2/b212066f/

  摘要：

  葡萄糖多巴胺（DA）衍生物可能代表一类新型DA前药，它们与存在于血脑屏障中的葡萄糖转运体GLUT-1相互作用，并在脑内生成DA。因此，通过酰胺、酯、氨基甲酸酯、肽或糖苷键将糖部分连接到DA的氨基或儿茶酚环上的化合物被合成出来。监测了这些化合物在不同介质中的前药行为，并研究了糖 conjugate 对人体红细胞中葡萄糖载体GLUT-1的亲和力。大多数化合物在缓冲液和血浆中显著稳定，几种化合物在与脑提取物共孵育时释放DA，且速率与DA与葡萄糖之间的连接键相关。与C-1和C-3取代的衍生物相比，在糖的C-6位取代的新型葡萄糖 conjugate 对葡萄糖转运的抑制作用更强。这项工作提供了关于取代葡萄糖与GLUT-1转运体相互作用的结构-活性信息。

  DOI：

  10.1039/b212066f

文献信息

• Compounds and Compositions for the Detection and Treatment of Alzheimer's Disease and Related Disorders
  申请人：Elmaleh David R.

  公开号：US20110060138A1

  公开（公告）日：2011-03-10

  One aspect of the present invention relates to compounds, compositions and methods for diagnosis and/or treatment of a subject suffering from an amyloidosis-associated pathological condition. In certain embodiments, the imaging and/or therapeutic agents of the instant invention may be administered to a subject for identification and/or treatment of amyloid deposits. A specific imaging method detects amyloid deposits by administering the imaging agent to the subject and detecting the spatial distribution of the agent. Differential accumulation of the agent is indicative of AD or an amyloidosis-associated pathological condition and can be monitored by using a PET or SPECT camera.

  本发明的一个方面涉及化合物、组合物和方法，用于诊断和/或治疗患有淀粉样变性相关病理状况的受试者。在某些实施例中，本发明的成像和/或治疗剂可以被注射给受试者，以便识别和/或治疗淀粉样沉积。一种特定的成像方法通过将成像剂注射给受试者并检测剂的空间分布来检测淀粉样沉积。剂的差异积累表明AD或淀粉样变性相关病理状况，并可以通过使用PET或SPECT相机进行监测。
• Compounds and compositions for the detection and treatment of Alzheimer's disease and related disorders
  申请人：The General Hospital Corporation

  公开号：US10857247B2

  公开（公告）日：2020-12-08

  One aspect of the present invention relates to compounds, compositions and methods for diagnosis and/or treatment of a subject suffering from an amyloidosis-associated pathological condition. In certain embodiments, the imaging and/or therapeutic agents of the instant invention may be administered to a subject for identification and/or treatment of amyloid deposits. A specific imaging method detects amyloid deposits by administering the imaging agent to the subject and detecting the spatial distribution of the agent. Differential accumulation of the agent is indicative of AD or an amyloidosis-associated pathological condition and can be monitored by using a PET or SPECT camera.

  本发明的一个方面涉及用于诊断和/或治疗淀粉样变性相关病症的化合物、组合物和方法。在某些实施方案中，本发明的成像剂和/或治疗剂可用于受试者淀粉样蛋白沉积的鉴定和/或治疗。具体的成像方法是通过向受试者施用成像剂并检测成像剂的空间分布来检测淀粉样蛋白沉积。淀粉样蛋白沉积物的不同程度的积聚表明了多发性硬化症或与淀粉样蛋白沉积相关的病理状况，可使用 PET 或 SPECT 相机进行监测。
• [EN] COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS<br/>[FR] COMPOSÉS ET COMPOSITIONS POUR LA DÉTECTION ET LE TRAITEMENT DE LA MALADIE D'ALZHEIMER ET DES TROUBLES ASSOCIÉS
  申请人：GEN HOSPITAL CORP

  公开号：WO2009117728A3

  公开（公告）日：2010-02-18
• COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS
  申请人：The General Hospital Corporation

  公开号：EP2268647A2

  公开（公告）日：2011-01-05
• US8450466B2
  申请人：——

  公开号：US8450466B2

  公开（公告）日：2013-05-28